{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammation+Eye", "query": { "condition": "Inflammation Eye" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 170, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammation+Eye&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T02:49:45.132Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02508337", "title": "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation", "Pain", "Cataract" ], "interventions": [ { "name": "XG-102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xigen SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2015-07", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02508337" }, { "nct_id": "NCT02786901", "title": "LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cataract", "Pain", "Ocular Inflammation" ], "interventions": [ { "name": "Loteprednol Etabonate Ophthalmic Gel dosed TID", "type": "DRUG" }, { "name": "Loteprednol Etabonate Ophthalmic Gel dosed BID", "type": "DRUG" }, { "name": "Vehicle Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2016-06", "completion_date": "2017-07-01", "has_results": true, "last_update_posted_date": "2021-01-08", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Quincy", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02786901" }, { "nct_id": "NCT02235272", "title": "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation", "Pain", "Cataract" ], "interventions": [ { "name": "XG-102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xigen SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 339, "start_date": "2014-09", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2017-01-24", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "Garden Grove, California", "locations": [ { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02235272" }, { "nct_id": "NCT04975971", "title": "A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anterior Chamber Inflammation", "Ocular Pain", "Corneal Edema", "Corneal Defect", "Penetrating KeratoPlasty", "Nuclear Cataract", "Cortical Cataract", "Cataract Senile" ], "interventions": [ { "name": "Dextenza 0.4Mg Ophthalmic Insert", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicole Fram M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-03-09", "completion_date": "2021-05-19", "has_results": false, "last_update_posted_date": "2021-07-26", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975971" }, { "nct_id": "NCT02026128", "title": "Optical Coherence Tomography (OCT) in Uveitis", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Uveitis" ], "interventions": [], "intervention_types": [], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2012-03", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02026128" }, { "nct_id": "NCT04130802", "title": "OCS-01 in Treating Inflammation and Pain in Post-cataract Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammation Corneal", "Pain, Postoperative" ], "interventions": [ { "name": "OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oculis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2019-09-27", "completion_date": "2020-01-31", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 4, "location_summary": "Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more", "locations": [ { "city": "Petaluma", "state": "California" }, { "city": "Roseburg", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04130802" }, { "nct_id": "NCT00001614", "title": "The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Arthritis, Juvenile Rheumatoid", "Uveitis" ], "interventions": [ { "name": "Chicken type II collagen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 13, "start_date": "1997-07", "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001614" }, { "nct_id": "NCT00430092", "title": "Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation" ], "interventions": [ { "name": "Difluprednate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sirion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 219, "start_date": null, "completion_date": null, "has_results": true, "last_update_posted_date": "2009-07-02", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "Washington, Missouri", "locations": [ { "city": "Washington", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00430092" }, { "nct_id": "NCT00958906", "title": "Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Uveitic Macular Edema", "Intraocular Inflammation" ], "interventions": [ { "name": "Infliximab (intravitreal, 2.0mg/0.05ml)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2009-08", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2011-06-23", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958906" }, { "nct_id": "NCT01431326", "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenovirus", "Anesthesia", "Anxiety", "Anxiolysis", "Autism", "Autistic Disorder", "Bacterial Meningitis", "Bacterial Septicemia", "Benzodiazepine", "Bipolar Disorder", "Bone and Joint Infections", "Central Nervous System Infections", "Convulsions", "Cytomegalovirus Retinitis", "Early-onset Schizophrenia Spectrum Disorders", "Epilepsy", "General Anesthesia", "Gynecologic Infections", "Herpes Simplex Virus", "Infantile Hemangioma", "Infection", "Inflammation", "Inflammatory Conditions", "Intra-abdominal Infections", "Lower Respiratory Tract Infections", "Migraines", "Pain", "Pneumonia", "Schizophrenia", "Sedation", "Seizures", "Skeletal Muscle Spasms", "Skin and Skin-structure Infections", "Treatment-resistant Schizophrenia", "Urinary Tract Infections", "Withdrawal", "Sepsis", "Gram-negative Infection", "Bradycardia", "Cardiac Arrest", "Cardiac Arrhythmia", "Staphylococcal Infections", "Nosocomial Pneumonia", "Neuromuscular Blockade", "Methicillin Resistant Staphylococcus Aureus", "Endocarditis", "Neutropenia", "Headache", "Fibrinolytic Bleeding", "Pulmonary Arterial Hypertension", "CMV Retinitis", "Hypertension", "Chronic Kidney Diseases", "Hyperaldosteronism", "Hypokalemia", "Heart Failure", "Hemophilia", "Heavy Menstrual Bleeding", "Insomnia" ], "interventions": [ { "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Benjamin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3520, "start_date": "2011-11", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-05-22T02:49:45.132Z", "location_count": 43, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431326" } ] }